Biopharma Plastic Market Report Scope & Overview:

The Biopharma Plastic Market size was valued at USD 6.07 billion in 2024 and is expected to reach USD 13.35 billion by 2032, growing at a CAGR of 10.37% over the forecast period of 2025-2032.

Growth in the biopharma plastic market is driven by single-use systems, polymer-based drug delivery, and sustainable biopharma materials. In 2025, a major biopharma plastics provider, such as Thermo Fisher Scientific, introduced the single-use 5L DynaDrive bioreactor to push forward the development of plastic-based bioreactors and sterile plastic parts. Biopharma plastic market trends, such as flexible biopharmaceutical packaging, medical plastics, and plastic tubing in pharmaceuticals for fluid management.

Reportedly, more than 140 individuals from 70+ suppliers and end-users have contributed to the biopharma plastic market analysis by providing best practices for disposable bioprocessing at the BPSA 2024's International Single-Use Summit. BPSA again released FAQs and a sustainability one-pager in 2025 to provide direction for biopharmaceutical manufacturing and polymer-based drug delivery solutions. It is the dynamic landscape that is molding the growing size of the biopharma plastic market with innovative biopharmaceutical packaging and disposable bioprocessing solutions designed around the world standard for quality.

Biopharma Plastic Market Dynamics:

Drivers:

• Surge in Modular Cleanroom Facilities Accelerates Biopharma Plastic Market Growth Globally

The growth of the biopharma plastics market is largely driven by the increase in modular construction of cleanrooms, the rising implementation of single-use technology in biopharma production, and the use of medical-grade plastics. G-CON Manufacturing collaborated with Pfizer to rapidly deploy modular cleanrooms in 2024. This increases the need for plastic bioreactors, plastic tubing for pharma, and sterile plastic components. With biopharmaceutical manufacturing trending towards flexible, smaller lots, biopharma plastic firms see that they have a higher biopharma plastic market share, and biopharma plastic market trends are more and more toward fast and scalable solutions in disposable bioprocessing and biopharmaceutical packaging.

• Government Funding for Cell and Gene Therapy Scales Biopharma Plastic Market Growth

Increasing government investment drives growth of the biopharma plastic market and fills in the biopharma plastic market size. In June 2024, NIH committed more than $100 million to support cell and gene therapy manufacturing. This trend stimulates the demand for single-use systems, plastic bioreactors, and specialized polymer-based drug delivery. Biopharma plastic enterprises are strong market share of biopharma plastic more and more, and biopharmaceutical packaging requirements are increasing with the scale of production. This trend bodes well for continued biopharma plastic market examination and growth of the disposable bioprocessing and medical-grade plastics markets.

Restraints:

• Fluctuating Energy Prices Increase Production Costs in Biopharma Plastic Manufacturing, Impeding Market Expansion

The biopharma plastic market size is significantly influenced by volatile energy prices, which increase the production price of medical-grade plastic and disposable bioprocessing products. Industrial electricity prices in the U.S. were 12% higher YoY in 2025, as per the U.S. EIA reports. Competitive pressures force biopharma plastic firms to strike a balance between cost pressures and the costs associated with polymer for drug delivery systems, plastics for bioreactors, and the packaging used by the biopharmaceutical industry. This sort of volatility makes analyzing the biopharma plastic market challenging and constraining the biopharma plastic market growth, as producers must adjust to cost fluctuations when satisfying worldwide demand.

Biopharma Plastic Market Segmentation Analysis:

By Material Type

Polypropylene (PP) dominated the Biopharma Plastic Market in 2024 with a 32.40% share due to exceptional chemical resistance and sterilization compatibility. PP, which complies with FDA cleanroom requirements and can withstand gamma sterilization, is commonly applied for disposable bioprocessing and polymer drug delivery. Demand is on the rise in the pharmaceutical plastic tubing and sterile plastic components used in large-scale biopharmaceutical production, according to SABIC. This trend, supported by biopharma plastic companies, strengthens biopharma plastic market share and is in line with the global shifts toward secure, one-time-use technology and biopharma packaging.

Polytetrafluoroethylene (PTFE) is the fastest-growing in the biopharma plastic market with a CAGR of 12.25% during the forecast period of 2025-2032, due to high-purity single-use systems being over demand. With its super chemical resistance, PTFE is the optimal material for high-demanding pharmaceutical plastic tubing and plastic bioreactors for advanced therapies. NIH's 2024 USD 100 million investment toward cell and gene therapy manufacturing has increased its uptake of it, subsequently increasing the biopharma plastic market size. PTFE's application aids the demand for complex biopharma materials, as it improves the performance of sterile plastic components and drives trends in the future biopharma plastic market.

By Product Type

Tubing dominated the Biopharma Plastic Market in 2024 with a 28.70% share, owing to its critical need for single-use systems. Spun from plastic bioreactors, depth filters, and polymer-based drug delivery components are linked by flexible tubing, allowing for aseptic flow of fluids. Demand jumped significantly with the shift of biopharmaceutical production to disposable bioprocessing, which contributed to the strong market share in the biopharma plastic category, according to Saint-Gobain Performance Plastics. This product category continues to be a staple among biopharma plastic suppliers, in line with industry demand for contamination control and scalable biopharma packaging.

Films & bags are the fastest growing in the biopharma plastic market with a CAGR of 11.21% during the forecast period of 2025-2032, due to the increased use of flexible bioreactors for folding purposes. Their development facilitates production at lower cost and scalability in cell therapy manufacturing. Thermo Fisher Scientific increased single-use bioreactor film production in 2024 to meet the demand. These medical-grade plastics provide operational flexibility, minimize cleaning validation, and are compatible with global biopharma plastic market analysis predicting strong growth of sterile plastic components and disposable bioprocessing products.

By Application

Containers dominated the biopharma plastic market in 2024 with a 27.40% share on account of their essential usage in sterile storage and sampling. They are used as a component of polymer-based drug delivery and within biopharmaceutical packaging to ensure the safe handling of the product. Gerresheimer AG reported that there was a rising demand for robust, compliant containers. This trend fuels investments made by biopharma plastic companies and ensures a steady biopharma plastic market share in the production and storage of biologics and advanced therapies.

Bioreactor bags are the fastest-growing in the biopharma plastic market with a CAGR of 11.60% during the forecast period of 2025-2032, driven by scalable manufacturing demand from cell and gene therapy production. These soft systems are easier on the upstream process and allow for lower cleaning and expense than the stainless-steel alternative. NIH’s 2024 investment of USD 100 million super-charged adoption; biopharma plastic market share trends reflected this change. Biopharma plastic companies meet demand with faster production with single-use bioreactor bags from medical-grade plastics.

By End-use

Pharmaceutical & biotechnology companies dominated the Biopharma Plastic Market in 2024 with a 52.60% share due to investment by the pharmaceutical & biotechnology companies in large-scale production of biologics. Their inclination toward disposable systems, plastic bioreactors, and polymer-based drug delivery systems escalates the market share for biopharma plastics. Growth in Pfizer capacity underscores demand for sterile plastic parts and compliant biopharma packaging. This is also consistent with analyses of the biopharma plastic market that innovation and ubiquitous production are likely to be the driving forces of market expansion.

Contract manufacturing organizations (CMOs) are the fastest growing in the biopharma plastic market with a CAGR of 11.03% during the forecast period of 2025-2032, as attributed to outsourcing in the advanced therapies. Smaller biotechs are increasingly dependent on CMOs for scaling up their viral vector and gene therapy production. Catalent’s involvement in gene therapy manufacturing is indicative of this burgeoning scale, driving demand for disposable bioprocessing equipment and medical plastics. This is in line with the demand for biopharma plastic, which then promotes greater flexibility and more regulatory compliance for biopharma plastic companies.

Biopharma Plastic Market Regional Outlook:

North America dominated the Biopharma Plastic Market in 2024 with a significant market share of 36.80% driven by the presence of a well-established biotechnology industry and the presence of a solid supporting industrial infrastructure. Biopharma plastic manufacturers in the U.S. enjoy mature regulatory environments, and sophisticated manufacturing requirements are resulting in demand for medical-grade plastics and sterile plastic parts. Local bioprocessing tubing expansion meets increased demand for biologics, says Saint-Gobain Performance Plastics. Additionally, a developing biopharmaceutical packaging industry in Canada further bolsters the biopharma plastic market share in the region and is a key driver for the growth of the biopharma plastic market.

The U.S. dominates North America’s Biopharma Plastic Market with a size of USD 1.84 billion in 2024 and is projected to reach a market size of USD 4.01 billion by 2032 with a market share of about 82%, supported by significant investment in polymer-based drug delivery and large-scale biopharmaceuticals manufacturing facilities. In 2024, Pfizer revealed major facility enlargements for the production of single-use systems and plastic-based bioreactors. The FDA’s guidance on current good manufacturing practice (cGMP) pushes the use of high-performance medical-grade plastics even more in pharmaceutical plastic tubing and disposable bioprocessing. Continued by this regulatory-backed innovation and infrastructure, this also propelled the U.S. share in the biopharma plastic market size, keeping them the front runners even in the domain of biopharma plastic market analysis.

Asia Pacific is the fastest-growing region with the highest CAGR of 10.87% during the forecast period of 2025-2032, with a growth in biopharma plastic companies and an increase in biopharmaceutical manufacturing capacity in the economically developing countries, including China, India, and Japan. Polymer-based drug delivery and disposable systems are promoted by government programs, including China’s 14th Five-Year Plan to drive domestic production. An expanding contract manufacturing market in India increases the disposable bioprocessing potential. Meanwhile, in Japan, investment in future-proof pharmaceutical plastic tubing technologies in Japan is gathering pace. This rapid evolution lifts the Biopharma Plastic Market Trends and infuses the market with intensely developing trends.

Biopharma Plastic Market Companies are:

The major biopharma plastic market competitors include Thermo Fisher Scientific Inc., Saint-Gobain Performance Plastics, West Pharmaceutical Services, Inc., Gerresheimer AG, Stevanato Group, Nemera, AptarGroup, Tekni-Plex, Inc., Berry Global Inc., SiO2 Medical Products, Ompi s.r.l., Spectrum Plastics Group, Catalent, Inc., Schott AG, Bormioli Pharma S.p.A., W. L. Gore & Associates, Inc., Plastipak Holdings, Inc., Tekni-Plex Healthcare, Freudenberg Medical, and Entegris, Inc.

Recent Developments:

• In June 2025, West Pharmaceutical Services inaugurated an advanced 18,000 m² manufacturing facility in Singapore to produce high‑precision single‑use system components and sterile plastic parts.

• In April 2025, Thermo Fisher Scientific introduced the 5 L DynaDrive single‑use bioreactor, enhancing process development efficiency and environmental sustainability in plastic‑based bioreactors.